Drug Profile
Research programme: Nav1.7 voltage-gated sodium channel inhibitors - SiteOne Therapeutics
Alternative Names: GTX analogues - SiteOne Therapeutics; Guanidinium toxin analogues - SiteOne Therapeutics; NaV1.7 inhibitors - SiteOne Therapeutics; Selective NaV1.7 channel blockers - SiteOne Therapeutics; Sodium ion channel 1.7 inhibitors - OneSite Therapeutics; ST Oral; ST SubQ; ST Topical; ST-2578Latest Information Update: 28 Nov 2022
Price :
$50
*
At a glance
- Originator Stanford University
- Developer SiteOne Therapeutics
- Class Analgesics; Antipruritics; Diagnostic agents; Imaging agents; Muscle relaxants; Small molecules
- Mechanism of Action Nav1.7 voltage-gated sodium channel inhibitors; Positron-emission tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Muscle hypertonia; Pain; Postoperative pain; Pruritus
Most Recent Events
- 28 Nov 2022 No recent reports of development identified for preclinical development in Postoperative-pain in USA (IV, Injection)
- 28 Oct 2022 No recent reports of development identified for research development in Pain in USA (SC)
- 28 Apr 2022 No recent reports of development identified for preclinical development in Pain in USA (PO)